Cholecystitis, Cholelithiasis
Conditions
Brief summary
The Study is designed to compare the effectiveness of Near Infrared Fluorescence Cholangiography (NIFC) to standard white light imaging (WLI) in visualizing and identifying the main biliary and hepatic structures (Cystic Duct, Right Hepatic Duct, Common Hepatic Duct, Common Bile Duct, Cystic-CBD junction, Cystic-Gallbladder junction and any Accessory Ducts) during laparoscopic cholecystectomy. The aim is to demonstrate that NIFC performs better than standard white light (WLI) alone in visualizing and identifying extra-hepatobiliary structures (Cystic Duct, Right Hepatic Duct, Common Hepatic Duct, Common Bile Duct, Cystic-CBD junction, Cystic-Gallbladder junction, and any Accessory Ducts) before and after dissection during Laparoscopic Cholecystectomy (LC).
Detailed description
Recently, a novel technique to visualize structures using fluorescent light and intravenous dye has been developed. Near Infrared Incisionless Fluorescent Cholangiography (NIFC) is a medical imaging technique that uses fluorescence to detect properly labeled structures during surgery. NIFC is performed using imaging devices with the purpose of providing real-time simultaneous information from color reflectance images (white light) and fluorescence emission (near infrared light). One or more light sources are used to excite and illuminate the sample. Light is collected using optical filters that match the emission spectrum of the fluorophore. Imaging lenses and digital cameras are used to produce the final image. During laparoscopic cholecystectomies, the visualization of the extra-hepatic bile ducts with fluorescence is called Near Infrared Incisionless Fluorescent Cholangiography (NIFC). Fluorescence equipment and a dye are necessary in order to perform a NIFC, but the technique requires no radiation or incision. A fluorescence dye is administrated intravenously at least 45 minutes before the surgery, which is excreted by the liver and the bile duct The Study is designed to compare the effectiveness of Near Infrared Fluorescence Cholangiography (NIFC) to standard white light imaging (WLI) in visualizing and identifying the main biliary and hepatic structures (Cystic Duct, Right Hepatic Duct, Common Hepatic Duct, Common Bile Duct, Cystic-CBD junction, Cystic-Gallbladder junction and any Accessory Ducts) during laparoscopic cholecystectomy. Eligible patients will be identified through clinical and test evaluation. Eligibility will be verified by the patient's primary surgeon. The surgeon will determine the indication and date of the surgery. Once a patient is confirmed as eligible, the surgeon will introduce the study in detail. If after being introduced to the study and having had the opportunity to ask questions, the patient is willing to participate, he/she will be asked to review and sign the informed consent document . Upon entry in the clinical trial patients will be randomly allocated to the intervention arm. Data will be collected at enrolment time, during surgery, at the end of surgery and one week after surgery. Upon entry in the clinical trial, the master study database (REDCap, will randomly allocated patients to one of the study arms (1:1) within site (1:1) using a computer generated random sequence. This will provide an allocation sequence for each site. Once a patient is enrolled and a database file in REDCap is initiated for that patient, he/she will be assigned electronically to one of the study arms. Patient will be blind to the intervention but surgeon blinding will not be feasible due to the nature of the intervention. The study will involve a considerable number of surgeons in each site, which should compensate any potential bias of some of them in favor or against either approach.
Interventions
Standard laparoscopic cholecystectomy with white light
Laparoscopic cholecystectomy in infrared light after injection of indocyanine green pre-operatively.
Sponsors
Study design
Eligibility
Inclusion criteria
1. Patients of both genders 2. Minimum age: 18 years old 3. Spoken and written command of the language spoken in the country's center 4. Ability to understand and follow the study procedures and sign the informed consent
Exclusion criteria
1. Known allergies to iodides 2. Known history of coagulopathy 3. Known moderate or severe liver disease Women who are pregnant or breastfeeding, or for whom possibility of pregnancy was not ruled out
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Detection Rate of Common Bile Duct Before and After Dissection Using Near Infra-red Light | Immediately before dissection (baseline) and immediately after dissection during the same surgical procedure. | Detection rate of the common bile duct during laparoscopic cholecystectomy, defined as the proportion of patients in whom the common bile duct was visualized immediately before dissection (baseline) and immediately after dissection using near infrared light. The detection rate was calculated separately for each arm and reported as the percentage of patients with successful identification. |
Countries
Argentina, Germany, Italy, Japan, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Xenon Light Laparoscopic cholecystectomy with Xenon Light
Laparoscopic cholecystectomy with Xenon light: Standard laparoscopic cholecystectomy with white light | 318 |
| Near Infrared Light Laparoscopic cholecystectomy with Near infrared light
Laparoscopic cholecystectomy with Xenon light: Standard laparoscopic cholecystectomy with white light
Laparoscopic cholecystectomy (fluorescent cholangiography): Laparoscopic cholecystectomy in infrared light after injection of indocyanine green pre-operatively. | 321 |
| Total | 639 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Insufficient data to analyze | 15 | 23 |
Baseline characteristics
| Characteristic | Xenon Light | Near Infrared Light | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 57 Participants | 57 Participants | 114 Participants |
| Age, Categorical Between 18 and 65 years | 261 Participants | 264 Participants | 525 Participants |
| Age, Continuous | 48.5 years STANDARD_DEVIATION 15.5 | 48.3 years STANDARD_DEVIATION 15 | 48.4 years STANDARD_DEVIATION 15.2 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 318 Participants | 321 Participants | 639 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 318 Participants | 321 Participants | 639 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants |
| Region of Enrollment Argentina | 96 participants | 104 participants | 200 participants |
| Region of Enrollment Germany | 106 participants | 111 participants | 217 participants |
| Region of Enrollment Italy | 33 participants | 31 participants | 64 participants |
| Region of Enrollment Japan | 0 participants | 1 participants | 1 participants |
| Region of Enrollment United States | 83 participants | 74 participants | 157 participants |
| Sex: Female, Male Female | 181 Participants | 218 Participants | 399 Participants |
| Sex: Female, Male Male | 137 Participants | 103 Participants | 240 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 1 / 318 | 0 / 321 |
| other Total, other adverse events | 4 / 318 | 1 / 321 |
| serious Total, serious adverse events | 2 / 318 | 0 / 321 |
Outcome results
Detection Rate of Common Bile Duct Before and After Dissection Using Near Infra-red Light
Detection rate of the common bile duct during laparoscopic cholecystectomy, defined as the proportion of patients in whom the common bile duct was visualized immediately before dissection (baseline) and immediately after dissection using near infrared light. The detection rate was calculated separately for each arm and reported as the percentage of patients with successful identification.
Time frame: Immediately before dissection (baseline) and immediately after dissection during the same surgical procedure.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Xenon Light | Detection Rate of Common Bile Duct Before and After Dissection Using Near Infra-red Light | Before Dissection | 64 Participants |
| Xenon Light | Detection Rate of Common Bile Duct Before and After Dissection Using Near Infra-red Light | After Dissection | 159 Participants |
| Near Infrared Light | Detection Rate of Common Bile Duct Before and After Dissection Using Near Infra-red Light | Before Dissection | 157 Participants |
| Near Infrared Light | Detection Rate of Common Bile Duct Before and After Dissection Using Near Infra-red Light | After Dissection | 243 Participants |